Selection of biologics for patients with metastatic colorectal cancer: The role of predictive markers

Pashtoon Murtaza Kasi, Joleen M Hubbard, Axel F Grothey

Research output: Contribution to journalArticle

7 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)273-276
Number of pages4
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Phenylurea Compounds
Antineoplastic Combined Chemotherapy Protocols
Recombinant Fusion Proteins
Pyridines
ras Proteins
Vascular Endothelial Growth Factor Receptor
Biological Factors
Biological Products
Patient Selection
Vascular Endothelial Growth Factor A
Colorectal Neoplasms
Biomarkers
Monoclonal Antibodies
Neoplasm Metastasis
regorafenib
panitumumab
Bevacizumab
aflibercept
Cetuximab

Keywords

  • aflibercept
  • bevacizumab
  • biologics
  • cetuximab
  • EGFR
  • metastatic colorectal cancer
  • panitumumab
  • RAS
  • regorafenib
  • VEGF

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Selection of biologics for patients with metastatic colorectal cancer : The role of predictive markers. / Kasi, Pashtoon Murtaza; Hubbard, Joleen M; Grothey, Axel F.

In: Expert Review of Gastroenterology and Hepatology, Vol. 9, No. 3, 01.03.2015, p. 273-276.

Research output: Contribution to journalArticle

@article{079cd32c18394b92abc9317761312cfc,
title = "Selection of biologics for patients with metastatic colorectal cancer: The role of predictive markers",
keywords = "aflibercept, bevacizumab, biologics, cetuximab, EGFR, metastatic colorectal cancer, panitumumab, RAS, regorafenib, VEGF",
author = "Kasi, {Pashtoon Murtaza} and Hubbard, {Joleen M} and Grothey, {Axel F}",
year = "2015",
month = "3",
day = "1",
doi = "10.1586/17474124.2015.1001743",
language = "English (US)",
volume = "9",
pages = "273--276",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Selection of biologics for patients with metastatic colorectal cancer

T2 - The role of predictive markers

AU - Kasi, Pashtoon Murtaza

AU - Hubbard, Joleen M

AU - Grothey, Axel F

PY - 2015/3/1

Y1 - 2015/3/1

KW - aflibercept

KW - bevacizumab

KW - biologics

KW - cetuximab

KW - EGFR

KW - metastatic colorectal cancer

KW - panitumumab

KW - RAS

KW - regorafenib

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84923306691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923306691&partnerID=8YFLogxK

U2 - 10.1586/17474124.2015.1001743

DO - 10.1586/17474124.2015.1001743

M3 - Article

C2 - 25579664

AN - SCOPUS:84923306691

VL - 9

SP - 273

EP - 276

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 3

ER -